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Background: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in a wide variety of epithelial cells including the
prostate subglandular epithelia. Previous studies have suggested that CFTR mutations and polymorphisms may be associated with several
cancers. Mutations and polymorphisms in the CFTR gene are responsible for cystic fibrosis (CF), and the incidence of prostate cancer in CF
patients seemed to be lower than expected.
Methods: A hospital-based case-control study was conducted including 230 prostate cancer patients and 230 age-matched controls. We used
nested PCR to analysis the IVS8-poly(T) tract and PCR-RFLP method to analysis the M470V polymorphism in CFTR gene.
Results: We observed an association of the low expression allele, IVS8-5T with prostate cancer protection (P=0.002; OR=0.281, 95%CI
0.120–0.658). Logistic regression analysis confirmed the 5T/7T genotype was in protective association with prostate cancer risk (P=0.003;
OR=0.232, 95%CI 0.090–0.599). Linkage disequilibrium between IVS8-poly(T) and M470V existed among prostate cancer patients (D′=
0.701). The low expression haplotype, “5T-V470” was found to be associated with protection against prostate cancer risk (P=0.010;
OR=0.324, 95%CI 0.132–0.796).
Conclusions: Our results indicate that the low expression CFTR polymorphisms may contribute to a reduced risk of prostate cancer in
Chinese Han population.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR polymorphisms; 5T allele; M470V; Prostate cancer1. Introduction
Prostate cancer is the most common malignancy in males
and the second-leading cause of cancer-related deaths in Europe
and North America [1]. But in Chinese, the incidence of
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doi:10.1016/j.jcf.2007.07.011evidences suggest that both genetics and environment contribute
to the development of prostate cancer [3].A large cohort study in
Scandinavia twins suggests that genetic factors may account for
as much as 42% of the prostate cancer risk [4], however, only
several rare highly penetrant genes have been identified to be
responsible for approximately 10% of this disease [3,5]. More
common low-penetrance polymorphisms may account for a
larger proportion of prostate cancer in the general population [3].
Mutations and polymorphisms in cystic fibrosis trans-
membrane conductance regulator (CFTR) gene are respon-
sible for cystic fibrosis (CF). Meanwhile, mutations and low-ed by Elsevier B.V. All rights reserved.
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in patients with various cancers, including pancreatic cancer
[6–10], melanoma [11,12], breast cancer [12,13], colon cancer
[12], and lung cancer [14,15]. Prostate cancer has been re-
ported in CF patients [16] and atypical CF patients [17], and
the incidence seemed to be lower than expected [16].
TheCFTR is a cyclic adenosine 5′-monophosphate (cAMP)-
regulated chloride channel (ClC), and is expressed in a wide
variety of epithelia [18], including the prostate subglandular
epithelial cells [19,20]. It is demonstrated that the CFTR is
crucial for normal function of epithelia. Nonfunctional CFTR
has been suggested to suppress tumor growth and proliferation
[21]. Mutations and polymorphisms in CFTR gene can cause
failure of CFTR, therefore may be involved in the pathogenesis
of some cancers [6–16]. It has been suggested that interactions
between CFTR polymorphisms and environmental factors
might play a role in the development of pancreatic cancer
[7,8]. Blockage of CFTR overlapping pathways have also been
used to explain the reduced invasiveness seen in human prostate
cancer cells [22–24]. However, it is necessary to conclusively
establish the role of CFTR variants as genetic factors for
carcinogenesis [24].
Genetic studies have found that functional polymorphisms
in the CFTR gene can alter the expression of CFTR [25].
Previous studies have suggested that the most frequent
polymorphism in CFTR gene, the M470V in exon 10, which
represents for A or G variation at position 470, plays a role in
modulating CFTR protein at both transcriptional and transla-
tional levels. It was reported that the M470 CFTR was
associated with a 1.7-fold of the V470 CFTR function [25].
Interestingly, the prevalence of V470 allele is strikingly low in
Sub-Saharan Africans and in African-Americans, with a fre-
quency approximately 1/5 of that in other populations [26].
And coincidentally, the black men have the highest incidence
of prostate cancer, about a 1.6-fold excess of white men [27],
and even about a 60-fold excess of Chinese [2]. In addition, the
polythymidine variants in intron 8 [IVS8-poly(T)] are asso-
ciated with the efficient usage of the intron 8 splicing acceptor
site, and affect the transcription of exon 9 mRNA by exon
skipping. The IVS8-5Tresults in approximately 90%of exon 9
skipping, leading to a nonfunctional CFTR, thereby is con-
sidered as a disease mutation with incomplete penetrance [28].
Based on these facts, we hypothesize that functional poly-
morphisms in CFTR gene may play a role in prostate cancer
susceptibility. Here, we examine two most frequent CFTR
functional polymorphisms, the IVS8-poly(T) and theM470V, in
230menwith prostate cancer and 230 age-matched controls. To
the best of our knowledge, this work is the first epidemiological
report of CFTR polymorphisms and prostate cancer risk.
2. Materials and methods
2.1. Subjects
Patients (n=230) with histologically confirmed prostate can-
cer (median age 72 years) were enrolled in this study betweenSeptember 2003 and July 2006 from theDepartment of Urology
of the first Affiliated Hospital of Nanjing Medical University.
Clinical characterization including age at diagnosis, preope-
rative serum prostate specific antigen (PSA) level, Gleason
grade, and disease status was obtained from medical records.
The control group consisted of 230 healthy men (median age
69 years) enrolled at the Health Checkup Center in Jiangsu
Provincial Research Institute of Geriatrics, with no evidence of
lung disease, pancreatitis, chronic rhinosinusitis, male infertility,
and neoplastic disease. All controls had PSA levels b4.0 ng/ml
and normal digital rectal exams (DRE).
All participants were ethnic Han Chinese living in Jiangsu
province, China. The study was approved by the ethical com-
mittee of Nanjing Medical University, and informed consent
was obtained from patients and controls.
2.2. Genotyping analysis
Genomic DNA was extracted from peripheral blood
leukocytes using the Chelex-100 method [29]. For ISV8-
poly(T) genotype analysis, a nested polymerase chain
reaction (PCR) was performed with a slight modification
to the method described previously by Chillon et al. [30].
The PCR protocol was 30 cycles using a PTC-100
thermal-cycler (MJ Research, USA) at 95 °C for 2 min
for denaturation, followed by 10 cycles at 94 °C for 1 min,
60 °C for 1 min, 70 °C for 1.5 min, then by an additional
20 cycles at 90 °C for 1 min, 60 °C for 1 min, 70 °C for
1.5 min and by a final extension at 60 °C for 30 min. The
reaction mixture contained 50 ng genomic DNA, 0.5 μM
of each primer, 10 mM Tris–HCl (pH 9.0), 50 mM KCl,
1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM of each
dNTP, and 0.75 unit Tag DNA polymerase (Promega,
USA) in a final volume of 25 ml. The PCR products were
denatured for 2 min 95 °C, mixed with STR 2× Loading
Solution (Promega, USA) and loaded onto 6% denaturing
polyacrylamide gel containing 8 M urea in an electropho-
resis apparatus (BIORAD Sequi-Gen GT System 38×
30 cm, CAT. no. 165-3862). Samples were run at 50 °C
for about 2 h. After electrophoresis, the gels were stained
with silver nitrate. Allele size determination was carried
out by comparison to an allele ladder.
Genotyping for M470V (rs213950) was carried out using
the polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) method, primers were designed
by online Primer 3 Software (http://cbr-rbc.nrc-cnrc.gc.ca/
cgi-bin/primer3_www.cgi): 5′-CAA GTG AAT CCT GAG
CGT GA-3′ (forward) and 5′-CAT CAA AGC ATG CCA
ACTAGA-3′ (reverse). PCR condition was the same as that
of IVS8-poly(T). The PCR products were 246 bp and were
subjected to enzymatic digestion with HphI enzyme at 37 °C
for about 18 h. After digestion, the M470 and 470V alleles
could be distinguished as fragments of 246 and 161 plus
85 bp, respectively. The digested products were submitted to
electrophoresis in 2% agarose gel and visualized by ethidium
bromide staining.
Table 2
Association between IVS8-poly(T) or M470V genotypes and prostate
cancer risk
Cases Controls OR a 95%CI P
7T/7T 222 201 Reference
5T/7T 7 24 0.232 0.090–0.599 0.003
7T/9T 1 5 0.197 0.019–2.264 0.197
M/M 46 43 Reference
M/V 114 113 0.659 0.370–1.176 0.158
V/V 70 74 0.663 0.352–1.247 0.202
M/V+V/V 214 187 0.660 0.381–1.145 0.140
Total 230 230
a OR: adjusted for age.
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Genotype and allele frequencies were calculated for
patients and controls. Conformity of the genotype distribu-
tion of the polymorphisms to Hardy–Weinberg equilibrium
was examined in the population under study. Fisher's exact
test was applied to compare categorical variables. Haplo-
types consisting of IVS8-poly(T) and M470V variants were
estimated by SHEsis algorithm introduced by Shi YYand He
L [31]. The odds ratio (OR) and its 95% confidence interval
(CI) was calculated as the measure of the association bet-
ween IVS8-poly(T) and M470V genotypes and prostate
cancer risk. Unconditional logistic regression was performed
using the SPSS 13.0 software (SPSS Inc, Chicago, IL, USA)
to compute OR and 95% CI to estimate relative risk of
prostate cancer associated with genotypes, with adjustment
for age. Two-tailed P-values less than 0.05 were considered
statistically significant.
3. Results
To determine the risk of CFTR polymorphisms for prostate
cancer, 230 prostate cancer cases and 230 controls were
genotyped for the IVS8-poly(T) and M470V polymorphisms.
The ages of the patients and the controls (mean±SD) were
71.5±7.4 (range 49–95) years and 70.7±9.8 (range 51–97)
years, respectively. There was no statistical difference betweenTable 1
Allele and genotype frequencies of CFTR gene polymorphisms in prostate
cancer cases and controls with odds ratio (OR)
Allele Cases (%) Controls (%) OR (95%CI) a P
(2n=460) (2n=460)
IVS8-poly(T)
7T 452 (98.26) 431 (93.70) 1.0
5T 7 (1.52) 24 (5.22) 0.281 (0.120–0.658) 0.002
9T 1 (0.22) 5 (1.09) 0.198 (0.023–1.704) 0.101
M470V
M 206 (44.78) 199 (43.26) 1.0
V 254 (55.22) 261 (56.74) 0.940 (0.725–1.220) 0.642
Genotype Cases (%) Controls (%)
(n=230) (n=230)
IVS8-poly(T)
7T/7T 222 (96.52) 201 (87.39) 1.0
5T/7T 7 (3.04) 24 (10.43) 0.269 (0.114–0.639) 0.002
7T/9T 1 (0.43) 5 (2.17) 0.197 (0.023–1.700) 0.101
HWE P-value 0.99 0.79
M/V 114 (49.57) 113 (49.13) 1.0
M/M 46 (20) 43 (18.70) 1.087(0.684–1.727) 0.723
V/V 70 (30.43) 74 (32.17) 0.922(0.622–1.368) 0.688
HWE P-value 0.97 0.99
a OR were calculated from the ratio of the number of alleles and genotypes
in interest versus all the other alleles or genotypes.the two groups. All alleles were in Hardy–Weinberg equi-
librium (HWE).
The frequencies of IVS8-poly (T) and M470Valleles and
genotypes in prostate cancer cases and controls are shown in
Table 1. The IVS8-7T allele was predominant both in cases
(98.26%) and in controls (93.70%). A statistically significant
difference was observed in the frequency of the CFTR low
expressing allele, the 5T, in prostate cancer patients (1.52%)
when compared with the control group (5.22%) (P=0.002;
OR=0.281, 95% CI 0.120–0.658). The 9T allele was rare
both in cases (0.22%) and in controls (1.09%), the difference
was not statistically significant (P=0.101). We did not find
any 5T or 9T homozygotes either in controls or in prostate
cancer patients. The 5T/7T genotype was significantly under-
represented among cases, and this genotype was therefore
associated with decreased susceptibility to prostate cancer
(3.04% vs. 10.43%; P=0.002; OR=0.269, 95% CI 0.114–
0.639). No statistically significant difference was observed in
7T/9T genotype between cases and controls (P=0.101).
The distribution of M470Valleles did not differ significant-
ly between prostate cancer patients and controls (P=0.642).
There was no statistical significance in the genotype distri-
bution of M470V polymorphism between the patients and
controls (P=0.897).
We also evaluated the strength of linkage disequilibrium for
the two polymorphisms in prostate cancer. In our data, linkage
disequilibrium between the two loci was shown among pa-
tients with prostate cancer (D′=0.701).
Prostate cancer risk estimates associated with the IVS8-
poly (T) and theM470V polymorphisms are shown in Table 2.
In logistic regression, when the IVS8-7T/7T genotype was
used as the reference group, the 5T/7T genotype was asso-
ciated with a reduced risk of prostate cancer (P=0.003;
OR=0.232, 95% CI 0.090–0.599) after adjustment for age.
We failed to find any association between the 7T/9T genotype
and prostate cancer susceptibility (P=0.197). For the M470V
polymorphism, the genotypes were not found to be associated
with the risk of prostate cancer.
Table 3 shows the results of haplotype analysis for IVS8-
poly(T) and M470V. The “7T-M470” haplotype and the “7T-
V470” haplotype account for 44.5% and 53.9% in patients
with prostate cancer respectively, the frequencies are not
significantly different between cases and controls. The “5T-
Table 3
Haplotype analysis of two polymorphic loci in CFTR gene
Haplotype Frequency a χ2 Fisher's P OR 95%CI
Case Control
7T-M 0.445 0.421 0.309 0.579 1.077 0.829–1.400
7T-V 0.539 0.521 0.093 0.760 1.041 0.802–1.352
5T-M 0.000 0.007 –
5T-V 0.014 0.042 6.659 0.010 0.324 0.132–0.796
9T-M 0.002 0.005 –
9T-V 0.000 0.005 –
Global result 6.688 0.035
a All those frequency b0.03 was ignored in the analysis.
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cancer cases compared with the controls (4.2%) (P=0.010;
OR=0.324, 95% CI 0.132–0.796).
This study is the first report on CFTR functional poly-
morphisms in the Chinese Han population living in the Main-
land.We found that the frequency of the 5Tallele inChinesewas
5.22%, which was comparable to ∼10% in Caucasians report-
ed preciously [30]. The distribution of M470V alleles (M/V,
43.26%/56.74%) was similar to that in other Asian populations
and Caucasians [32,33], but was strikingly different from that in
Sub-Saharan Africans (M/V, 97.5%/2.5%) and African Amer-
icans (M/V, 89.1%/10.9%) [25].
4. Discussion
The present study first investigates the association bet-
ween functional polymorphisms in CFTR gene and prostate
cancer risk, and adds to the growing body of evidence that
CFTR may be involved in the pathogenesis of some cancers.
In our study, the prevalence of IVS8-5T in Chinese Han
prostate cancer patients is approximately one third that in the
general population, and the risk of prostate cancer for an indi-
vidual with a 5T background is about one fourth. Previously,
most of the studies on 5T in cancer risk have been in pancreatic
cancer [7–9]. Those studies failed to find statistically signi-
ficant association between 5T and pancreatic cancer. However,
they pointed to the possibility thatCFTR polymorphisms inter-
actingwith potential genetic and environmental cofactorsmight
play a role in the pathogenesis of pancreatic cancer [7,9]. The
somewhat contradictory findings between our study and the
studies in pancreatic cancer may be partly explained by dif-
ferent level of CFTR expression and by varying sensitivities of
individual organs [34].
To our knowledge, no epidemiologic studies have in-
vestigated the role ofM470V polymorphism in cancer risks. In
this study, no significant independent associations with pro-
state cancer were observed for the M470V polymorphism.
However, we found that the V470 CFTR has a nonsignificant
negative trend in the prostate cancer susceptibility. In future
larger study series, the V470 allele would have shown a
protective association with prostate cancer.M470V polymorphism conferred a modulation in the pene-
trance of IVS8-poly(T), and the 5T-V470 haplotype has been
shown to have higher disease association than the 5T-M470
haplotype [25]. In this study, linkage equilibrium test and
haplotype analysis showed a decreased frequency of 5T asso-
ciated with V470 in prostate cancer cases, suggesting that the
protective effect of 5T against prostate cancer would be en-
hanced by the combination with V470.
Besides IVS8-poly(T) and M470V, IVS8-(TG)m immedi-
ately adjacent to poly(T) is another functional polymorphism in
CFTR gene. Longer (TG)m tracts favor the disease penetrance
of the 5Tallele [25,35], and the disease risk for males with 5T-
TG11 is 0.10, 5T-TG12 is 0.78, and 5T-TG13 is 1.0 [35].
However, the distribution of TG13 allele is very low in Asian,
with a frequency of ∼2.1% [32,33], larger scale studies are
needed to further investigate the significant association with
(TG)m and poly(T) polymorphisms in prostate cancer.
The 5T and V470 may impair the quantity and quality of
CFTR protein [25,28]. The CFTR plays a key role in the
maintenance of epithelium homeostasis and participates in
a plethora of functions mediated by different cellular path-
ways [36]. It has been shown that dysfunctional CFTR was
responsible for elevated blood ATP concentrations in mice
and in CF patients [21,37]. Elevated extracellular ATP was
demonstrated to inhibit tumor growth [38,39]. Likewise,
previous observations have suggested that, many types of
CFTR overlapping pathways, such as Na+, Ca2+, K+ and Cl−
channels, contributed to the development of prostate cancer
cell lines [22,23]. Up-regulation of these channels can stim-
ulate and blockage of them can suppress the growth and
proliferation of human prostate cancer cells [22–24]. These
results suggested that functional CFTR may strengthen the
ability of the prostate cancer cells to survive by handling
proliferative homeostasis and thereby diminishing their pro-
apoptotic potential [23]. It is in need of further evidences to
address the intriguing possibility that CFTR polymorphisms
and mutations may contribute to or protect against the risk
for prostate cancer.
In summary, in this hospital-based case-control study, we
first analyzed CFTR functional polymorphisms in patients
with prostate cancer in Chinese Han population. We found
that the low expression of CFTR polymorphism, IVS8-5T,
may protect against prostate cancer, and its pathogenic
potential may be modulated by the M470V polymorphism.
Our study emphasizes that it is necessary to conclusively
establish the role of functional polymorphisms in CFTR
gene as protective or susceptible genetic factors for prostate
cancer, and to investigate the significance of CFTR protein in
the pathogenesis of prostate cancer.Acknowledgements
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